Literature DB >> 16545687

Increased urinary excretion of 8-iso-prostaglandin F2alpha in patients with HFE-related hemochromatosis: a case-control study.

G D Kom1, E Schwedhelm, P Nielsen, R H Böger.   

Abstract

The hypothesis according to which iron overload could be harmful has been extensively and controversially discussed in the literature. One underlying pathological mechanism may be elevated oxidative stress. Thus, we studied the correlation between hemochromatosis and an established marker of oxidative stress, 8-iso-prostaglandin F2alpha (8-iso-PGF2alpha, iPF2alpha-III, 15-F2t-IsoP). We enrolled 21 patients with hemochromatosis, positive for the homozygous C282Y mutation in the HFE gene, and 21 healthy controls frequency-matched by age and gender in a case-control study design. The objective was to show that iron overload in HFE-related hemochromatosis is associated with increased oxidative stress assessed through 8-iso-PGF(2alpha) urinary excretion, and that oxidative stress is impacted by iron-removal treatment (phlebotomy). Study parameters were transferrin saturation, 8-iso-PGF(2alpha) urine excretion, transferrin, ferritin, serum iron, and vitamins A and E for all participants. Iron concentration in the liver and non-transferrin-bound iron were measured in patients only. We found a significant difference in 8-iso-PGF2alpha in patients (245 [interquartile range 157-348] pg/mg creatinine) compared with controls (128 [106-191] pg/mg creatinine, P = 0.002). Vitamin A was significantly reduced in cases (0.34 [0.25-1.83] microg/ml compared to 3.00 [2.11-3.39] microg/ml, P < 0.001), while vitamin E did not show a significant difference in cases (14.7 [11.5-18.1] microg/ml) compared with controls (14.9 [13.1-19.2] microg/ml, P = 0.52). After phlebotomy treatment and normalization of the iron parameters in the hemochromatosis group, serum vitamin A levels were significantly increased (1.36 [1.08-1.97] microg/ml, P = 0.035 vs. baseline, P < 0.001 vs. controls) and 8-iso-PGF2alpha urinary excretion was lowered to control levels (146 [117-198] pg/mg creatinine, P = 0.38 vs. controls). In our study, HFE-related hemochromatosis was associated with increased oxidative stress and hypovitaminemia A in C282Y homozygotes. The increased oxidative stress was reversible by normalization of the iron load by phlebotomy. Thus, phlebotomy is an effective and adequate means for reducing oxidative stress in these patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16545687     DOI: 10.1016/j.freeradbiomed.2005.11.004

Source DB:  PubMed          Journal:  Free Radic Biol Med        ISSN: 0891-5849            Impact factor:   7.376


  10 in total

1.  Genetic and environmental influences on oxidative damage assessed in elderly Danish twins.

Authors:  Kasper Broedbaek; Rasmus Ribel-Madsen; Trine Henriksen; Allan Weimann; Morten Petersen; Jon T Andersen; Shoaib Afzal; Brian Hjelvang; L Jackson Roberts; Allan Vaag; Pernille Poulsen; Henrik E Poulsen
Journal:  Free Radic Biol Med       Date:  2011-02-24       Impact factor: 7.376

2.  Heterologous downregulation of vasopressin type 2 receptor is induced by transferrin.

Authors:  Richard Bouley; Paula Nunes; Billy Andriopoulos; Margaret McLaughlin; Matthew J Webber; Herbert Y Lin; Jodie L Babitt; Thomas J Gardella; Dennis A Ausiello; Dennis Brown
Journal:  Am J Physiol Renal Physiol       Date:  2012-12-12

3.  Paraoxonase-1 status in patients with hereditary hemochromatosis.

Authors:  Nicola Martinelli; Anabel García-Heredia; Helena Roca; Núria Aranda; Victoria Arija; Bharti Mackness; Michael Mackness; Fabiana Busti; Gerard Aragonès; Juan Pedro-Botet; Federica Pedica; Ivana Cataldo; Judit Marsillach; Jorge Joven; Domenico Girelli; Jordi Camps
Journal:  J Lipid Res       Date:  2013-03-06       Impact factor: 5.922

4.  Higher serum iron is associated with increased oxidant stress in HIV-infected men.

Authors:  Matthew B Crist; Vlada V Melekhin; Aihua Bian; Ayumi Shintani; Ginger L Milne; Asha R Kallianpur; Leigh A Dageforde; David W Haas; Todd Hulgan
Journal:  J Acquir Immune Defic Syndr       Date:  2013-12-01       Impact factor: 3.731

5.  Hemochromatosis (HFE) Gene Variants Are Associated with Increased Mitochondrial DNA Levels During HIV-1 Infection and Antiretroviral Therapy.

Authors:  Asha R Kallianpur; Mariana Gerschenson; Todd Hulgan; Harpreet Kaur; David B Clifford; David W Haas; Deborah G Murdock; Justin C McArthur; David C Samuels; David M Simpson
Journal:  AIDS Res Hum Retroviruses       Date:  2018-08-22       Impact factor: 2.205

Review 6.  Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson's, Huntington's, Alzheimer's, prions, bactericides, chemical toxicology and others as examples.

Authors:  Douglas B Kell
Journal:  Arch Toxicol       Date:  2010-08-17       Impact factor: 5.153

7.  Should HFE p.C282Y homozygotes with moderately elevated serum ferritin be treated? A randomised controlled trial comparing iron reduction with sham treatment (Mi-iron).

Authors:  Sim Yee Ong; Lara Dolling; Jeannette L Dixon; Amanda J Nicoll; Lyle C Gurrin; Michelle Wolthuizen; Erica M Wood; Greg J Anderson; Grant A Ramm; Katrina J Allen; John K Olynyk; Darrell Crawford; Jennifer Kava; Louise E Ramm; Paul Gow; Simon Durrant; Lawrie W Powell; Martin B Delatycki
Journal:  BMJ Open       Date:  2015-08-12       Impact factor: 2.692

Review 8.  From Environment to Genome and Back: A Lesson from HFE Mutations.

Authors:  Raffaela Rametta; Marica Meroni; Paola Dongiovanni
Journal:  Int J Mol Sci       Date:  2020-05-15       Impact factor: 5.923

9.  Personalized medicine in human space flight: using Omics based analyses to develop individualized countermeasures that enhance astronaut safety and performance.

Authors:  Michael A Schmidt; Thomas J Goodwin
Journal:  Metabolomics       Date:  2013-06-27       Impact factor: 4.290

Review 10.  Atypical juvenile hereditary hemochromatosis onset with positive pancreatic islet autoantibodies diabetes caused by novel mutations in HAMP and overall clinical management.

Authors:  Hui-Xuan Wu; Jun-Ying Liu; De-Wen Yan; Long Li; Xiang-Hua Zhuang; Hai-Yan Li; Zhi-Guang Zhou; Hou-De Zhou
Journal:  Mol Genet Genomic Med       Date:  2020-10-05       Impact factor: 2.183

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.